Data as of .
PBE vs PBPH: which is really different?
PBE and PBPH hold 16% of their weight in the same names.
ETFIQ Off-Index Score: PBE scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
16% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, PBE and PBPH hold 16% of their money in the same securities at the same weight.
| Holding | PBE | PBPH |
|---|---|---|
| Amgen Inc | 4.53% | 4.33% |
| Gilead Sciences Inc | 5.27% | 4.10% |
| Natera Inc | 5.70% | 0.71% |
| Biogen Inc | 5.07% | 0.62% |
| United Therapeutics Corp | 2.70% | 0.52% |
| Incyte Corp | 2.73% | 0.46% |
| BioMarin Pharmaceutical Inc | 2.74% | 0.24% |
| Exelixis Inc | 2.91% | 0.24% |
| Only in PBE | Only in PBPH |
|---|---|
| Illumina Inc 5.53% | ELI LILLY & CO 14.74% |
| Regeneron Pharmaceuticals Inc 4.89% | JOHNSON & JOHNSON 9.10% |
| Royalty Pharma PLC 4.88% | ABBVIE INC 6.53% |
| Vertex Pharmaceuticals Inc 4.77% | ROCHE HOLDING AG-GENUSSCHEIN 5.28% |
| Novavax Inc 3.03% | NOVARTIS AG-REG 4.99% |
| Sarepta Therapeutics Inc 3.01% | MERCK & CO. INC. 4.71% |
| Halozyme Therapeutics Inc 2.91% | ASTRAZENECA PLC 4.60% |
| TG Therapeutics Inc 2.91% | NOVO NORDISK A/S-B 4.37% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jan 31, 2026 and Sep 19, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| PBE | PBPH | PBE | PBPH | PBE | PBPH | |
| 3 months | +13.2% | +12.4% | +11.0 pts | +10.1 pts | +15.7 pts | +14.8 pts |
| 6 months | +25.9% | +15.6% | +7.8 pts | −2.5 pts | +1.6 pts | −8.7 pts |
| 1 year | +36.2% | not published | +19.6 pts | not published | +14.4 pts | not published |
| 3 years | +65.0% | not published | −13.4 pts | not published | −33.1 pts | not published |
| Since launch | +492.4% | +13.3% | −311.1 pts | −0.8 pts | −1197.8 pts | −5.7 pts |
| PBE Invesco Biotechnology & Genome ETF Holds 33 stocks in biotech, 30% of its weight in S&P 500 companies | PBPH Portfolio Building Block World Pharma and Biotech Index ETF Holds 51 stocks in biotech, 57% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | Invesco | Portfolio Building Block |
| Theme | Biotech | Biotech |
| In the S&P 500 | 30.0% | 56.8% |
| Active share vs the S&P 500 | 99.0% | 95.0% |
| In the Nasdaq-100 | 19.5% | 14.7% |
| Holdings | 33 | 51 |
| Top ten, share of the fund | 46.7% | 62.7% |
| Expense ratio | 0.59% | 0.13% |
| Fee for the differing part | 0.60% | 0.14% |
| Total return, 1 year | +36.2% | +13.3% (since launch on Nov 25, 2025) |
| vs the S&P 500 | +19.6 pts | −0.8 pts |
| vs the Nasdaq-100 | +14.4 pts | −5.7 pts |
| Below its high | −3.9% | −4.8% |
| Net assets | $414m | $36m |
PBE in plain words
By weight, 30% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 47% of the fund across 33 positions, as published by its issuer for Sep 19, 2026. Over the year to Sep 18, 2026 the fund returned +36.2% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 19.6 pts.
PBPH in plain words
By weight, 57% of PBPH's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 95%. The top ten holdings are 63% of the fund across 51 positions, as filed for Jan 31, 2026. Since it launched on Nov 25, 2025 the fund returned +13.3% with distributions reinvested against +14.1% for the S&P 500, so a holder was behind by 0.8 pts.
Questions people ask
- Do PBE and PBPH hold the same stocks?
- By their latest filings, 16% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, PBE or PBPH?
- PBE has 30% of its weight in S&P 500 names and PBPH has 57%, so PBE differs more from the index.
- Which is cheaper, PBE or PBPH?
- PBE charges 0.59% a year and PBPH charges 0.13%, so PBPH is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, PBE against PBPH, data as of Sep 18, 2026. https://etfiq.com/compare/themes/pbe-vs-pbph Free to use with attribution; the underlying files are at Open data.